Interaction of factors related to the metabolic syndrome and vitamin D on risk of prostate cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 2, 2007, Pages 302-307

  Tuohimaa, Pentti ^a   Tenkanen, Leena ^c   Syvälä, Heimo ^a   Lumme, Sonja ^c   Hakulinen, Timo ^d   Dillner, Joakim ^e   Hakama, Matti ^b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b UNIVERSITY OF TAMPERE   (Finland)

^c Helsinki Heart Study   (Finland)

^d FINNISH CANCER REGISTRY   (Finland)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; VITAMIN D;

ADULT; ARTICLE; BODY MASS; CANCER RISK; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; PROSTATE CANCER; SYSTOLIC BLOOD PRESSURE;

ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; FINLAND; HUMANS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK FACTORS; VITAMIN D;

EID: 33847707281     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-0777     Document Type: Article

References (60)

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
2. Grundy SM, Brewer HB, Jr., Cleeman JI, Smith SC, Jr., Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 2004;24:e13-8.
3. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005;293:194-202.
4. Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomarkers Prev 2004;13:1646-50.
5. Hammarsten J, Hogstedt B. Clinical, haemodynamic, anthropometric, metabolic, and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Press 2004;13:47-55.
6. Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol 2002;3:565-74.
7. O'Malley RL, Taneja SS. Obesity and prostate cancer. Can J Urol 2006;13 Suppl 2:11-7.
8. Andersson SO, Wolk A, Bergstrom R, et al. Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. J Natl Cancer Inst 1997;89:385-9.
9. Engeland A, Tretli S, Bjorge T. Height body mass index, and prostate cancer: a follow-up of 950000 Norwegian men. Br J Cancer 2003;89:1237-42.
10. Giovannucci E, Rimm EB, Liu Y, et al. Body mass index and risk of prostate cancer in U.S. health professionals. J Natl Cancer Inst 2003;95:1240-4.
11. Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 2004;47:1071-8.
12. Gonzalez-Perez A, Garcia Rodriguez LA. Prostate cancer risk among men with diabetes mellitus (Spain). Cancer Causes Control 2005;16:1055-8.
13. Tande AJ, Platz EA, Folsom AR. The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol 2006;164:1094-102.
14. Lund Haheim L, Wisloff TF, Holme I, Nafstad P. Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol 2006;164:769-74.
15. Hanchette CL, Schwartz GG. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 1992;70:2861-9.
16. Corder EH, Guess HA, Hulka BS, et al. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 1993;2:467-72.
17. Luscombe CJ, Fryer AA, French ME, et al. Exposure to ultraviolet radiation: association with susceptibility and age at presentation with prostate cancer. Lancet 2001;358:641-2.
18. Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 2000;11:847-52.
19. Grant WB. An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer 2002;94:1867-75.
20. Colli JL, Colli A. International comparisons of prostate cancer mortality rates with dietary practices and sunlight levels. Urol Oncol 2006;24:184-94.
21. Schwartz GG, Hanchette CL. UV, latitude, and spatial trends in prostate cancer mortality: all sunlight is not the same (United States). Cancer Causes Control 2006;17:1091-101.
22. Ruijter E, van de Kaa C, Miller G, Ruiter D, Debruyne F, Schalken J. Molecular genetics and epidemiology of prostate carcinoma. Endocr Rev 1999;20:22-45.
23. Feldman D, Zhao XY, Krishnan AV. Editorial/mini-review: vitamin D and prostate cancer. Endocrinology 2000;141:5-9.
24. Freedman DM, Dosemeci M, McGlynn K. Sunlight and mortality from breast, ovarian, colon, prostate, and non-melanoma skin cancer: a composite death certificate based case-control study. Occup Environ Med 2002;59:257-62.
25. Terry P, Lichtenstein P, Feychting M, Ahlbom A, Wolk A. Fatty fish consumption and risk of prostate cancer. Lancet 2001;357:1764-6.
26. Taylor JA, Hirvonen A, Watson M, Pittman G, Mohler JL, Bell DA. Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res 1996;56:4108-10.
27. Ingles SA, Ross RK, Yu MC, et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor [see comments]. J Natl Cancer Inst 1997;89:166-70.
28. Ma J, Stampfer MJ, Gann PH, et al. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomarkers Prev 1998;7:385-90.
29. Habuchi T, Suzuki T, Sasaki R, et al. Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. Cancer Res 2000;60:305-8.
30. Hamasaki T, Inatomi H, Katoh T, Ikuyama T, Matsumoto T. Clinical and pathological significance of vitamin D receptor gene polymorphism for prostate cancer which is associated with a higher mortality in Japanese. Endocr J 2001;48:543-9.
31. Braun MM, Helzlsouer KJ, Hollis BW, Comstock GW. Prostate cancer and prediagnostic levels of serum vitamin D metabolites. Cancer Causes Control 1995;6:235-9.
32. Gann PH, Ma J, Hennekens CH, Hollis BW, Haddad JG, Stampfer MJ. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev 1996;5:121-6.
33. Nomura AMY, Stemmermann GN, Lee J, et al. Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control 1998;9:425-32.
34. Tuohimaa P, Tenkanen L, Ahonen M, et al. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer 2004;108:104-8.
35. Boucher BJ. Inadequate vitamin D status: does it contribute to the disorders comprising syndrome 'X'? Br J Nutr 1998;79:315-27.
36. Ye WZ, Reis AF, Dubois-Laforgue D, Bellanne-Chantelot C, Timsit J, Velho G. Vitamin D receptor gene polymorphisms are associated with obesity in type 2 diabetic subjects with early age of onset. Eur J Endocrinol 2001;145:181-6.
37. Ford ES, Ajani UA, McGuire LC, Liu S. Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. Diabetes Care 2005;28:1228-30.
38. Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001;358:1500-3.
39. Ortlepp JR, Lauscher J, Hoffmann R, Hanrath P, Joost HG. The vitamin D receptor gene variant is associated with the prevalence of type 2 diabetes mellitus and coronary artery disease. Diabet Med 2001;18:842-5.
40. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45.
41. Antoniucci DM, Black DM, Sellmeyer DE. Serum 25-hydroxyvitamin D is unaffected by multiple freeze-thaw cycles. Clin Chem 2005;51:258-61.
42. Tuohimaa P, Lyakhovich A, Aksenov N, et al. Vitamin D and prostate cancer. J Steroid Biochem Mol Biol 2001;76:125-34.
43. Shulman AI, Mangelsdorf DJ. Retinoid x receptor heterodimers in the metabolic syndrome. N Engl J Med 2005;353:604-15.
44. Peehl DM, Feldman D. The role of vitamin D and retinoids in controlling prostate cancer progression. Endocr Relat Cancer 2003;10:131-40.
45. Peehl DM, Feldman D. Interaction of nuclear receptor ligands with the vitamin D signaling pathway in prostate cancer. J Steroid Biochem Mol Biol 2004;92:307-15.
46. Stewart LV, Weigel NL. Vitamin D and prostate cancer. Exp Biol Med (Maywood) 2004;229:277-84.
47. Attia N, Tamborlane WV, Heptulla R, et al. The metabolic syndrome and insulin-like growth factor I regulation in adolescent obesity. J Clin Endocrinol Metab 1998;83:1467-71.
48. Kurosu H, Yamamoto M, Clark JD, et al. Suppression of aging in mice by the hormone Klotho. Science 2005;309:1829-33.
49. Tsujikawa H, Kurotaki Y, Fujimori T, Fukuda K, Nabeshima Y. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol 2003;17:2393-403.
50. Unger RH. Klotho-induced insulin resistance: a blessing in disguise? Nat Med 2006;12:56-7.
51. Papatsoris AG, Karamouzis MV, Papavassiliou AG. Novel insights into the implication of the IGF-1 network in prostate cancer. Trends Mol Med 2005;11:52-5.
52. Iwamura M, Sluss PM, Casamento JB, Cockett AT. Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines. Prostate 1993;22:243-52.
53. Boyle BJ, Zhao XY, Cohen P, Feldman D. Insulin-like growth factor binding protein-3 mediates 1α,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol 2001;165:1319-24.
54. Sprenger CC, Peterson A, Lance R, Ware JL, Drivdahl RH, Plymate SR. Regulation of proliferation of prostate epithelial cells by 1,25- dihydroxyvitamin D3 is accompanied by an increase in insulin-like growth factor binding protein-3. J Endocrinol 2001;170:609-18.
55. Yamagishi T, Saito Y, Nakamura T, et al. Troglitazone improves endothelial function and augments renal klotho mRNA expression in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with multiple atherogenic risk factors. Hypertens Res 2001;24:705-9.
56. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002;110:229-38.
57. Lamberg-Allardt C, Kirjarinta M, Dessypris AG. Serum 25-hydroxy-vitamin D, parathyroid hormone and calcium levels in adult inhabitants above the arctic circle in Northern Finland. Ann Clin Res 1983;15:142-5.
58. Wolk A. Diet, lifestyle, and risk of prostate cancer. Acta Oncol 2005;44:277-81.
59. Nunez NP, Liu H, Meadows GG. PPAR-γ ligands and amino acid deprivation promote apoptosis of melanoma, prostate, and breast cancer cells. Cancer Lett 2006;236:133-41.
60. Yao CJ, Lai GM, Chan CF, Cheng AL, Yang YY, Chuang SE. Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone. Int J Cancer 2006;118:773-9.